Dendreon, Geron jobs cut after Valeant, Janssen deals
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals pulled Dendreon out of bankruptcy by acquiring the troubled prostate cancer immunotherapy company, and Johnson & Johnson's Janssen Biotech subsidiary pumped much-needed cash into Geron with a drug development partnership, but because of those deals 95 people at Dendreon and Geron are losing their jobs.